2024-03-29T14:34:29Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/148712023-05-17T09:41:57Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2060com_20.500.12105_2052col_20.500.12105_16977col_20.500.12105_2061
00925njm 22002777a 4500
dc
Gonzalez-Perez, Maria
author
Montes-Casado, Maria
author
Conde-San Román, Patricia
author
Cervera Hernandez, Isabel
author
Baranda Prellezo, Jana
author
Berges-Buxeda, Marcos Joaquín
author
Perez-Olmeda, Mayte
author
Sanchez-Tarjuelo, Rodrigo
author
Utrero-Rico, Alberto
author
Lozano-Ojalvo, Daniel
author
Torre, Denis
author
Schwarz, Megan
author
Guccione, Ernesto
author
Camara, Carmen
author
Llópez-Carratalá, M Rosario
author
Gonzalez-Parra, Emilio
author
Portoles, Pilar
author
Ortiz, Alberto
author
Portoles, Jose
author
Ochando, Jordi
author
2022-03-23
Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population.
Front Immunol. 2022 Mar 23;13:845882.
http://hdl.handle.net/20.500.12105/14871
35401504
10.3389/fimmu.2022.845882
1664-3224
Frontiers in Immunology
COVID-19
SARS-CoV-2 vaccine
Cellular response
Chronic kidney disease
Hemodialysis
Humoral response
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination